Boai NKY Medical Holdings (300109) Fundamentals 2026 — P/E 39.3x, Revenue Analysis | SniperIQ
Boai NKY Medical Holdings (300109) is a CN-listed Basic Materials company in Chemicals - Specialty with a market capitalization of ¥6.6B, trading at ¥13.66 on the SHZ. This SniperIQ fundamentals page covers Boai NKY Medical Holdings's valuation (P/E 39.3x, P/B 1.8x), profitability (net margin 14.6%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Boai NKY Medical Holdings's market cap?
Boai NKY Medical Holdings (300109) has a market capitalization of approximately ¥6.6B, trading at ¥13.66 on the SHZ. Market cap moves with the live share price.
What is Boai NKY Medical Holdings's P/E ratio?
Boai NKY Medical Holdings's trailing twelve-month P/E ratio is 39.3x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Boai NKY Medical Holdings?
Boai NKY Medical Holdings runs a net profit margin of 14.6%, a gross margin of 45.6%, and an operating margin of 25.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Boai NKY Medical Holdings generate?
Boai NKY Medical Holdings reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥190M and earnings per share (EPS) of 0.39. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Boai NKY Medical Holdings pay a dividend?
Boai NKY Medical Holdings offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Boai NKY Medical Holdings financially healthy?
Boai NKY Medical Holdings carries a debt-to-equity ratio of 0.09x and a current ratio of 3.21x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Boai NKY Medical Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Boai NKY Medical Holdings (300109) the key facts are: market cap ¥6.6B, P/E 39.3x, revenue ¥1.2B, 52-week range 12.35-17.59167. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Boai NKY Medical Holdings's full fundamentals live
Get Boai NKY Medical Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.